ENANTA PHARMACEUTICALS INC's ticker is ENTA and the CUSIP is 29251M106. A total of 173 filers reported holding ENANTA PHARMACEUTICALS INC in Q3 2020. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,197,881 | -76.9% | 196,753 | -55.8% | 0.00% | -66.7% |
| Q2 2023 | $9,532,044 | -56.2% | 445,442 | -17.3% | 0.00% | -57.1% |
| Q1 2023 | $21,783,606 | +86045.5% | 538,689 | -0.9% | 0.01% | 0.0% |
| Q4 2022 | $25,287 | -99.9% | 543,566 | +6.6% | 0.01% | -30.0% |
| Q3 2022 | $26,449,000 | +6.8% | 509,878 | -2.6% | 0.01% | +11.1% |
| Q2 2022 | $24,756,000 | -41.4% | 523,709 | -11.8% | 0.01% | -30.8% |
| Q1 2022 | $42,244,000 | -6.1% | 593,520 | -1.4% | 0.01% | -7.1% |
| Q4 2021 | $44,998,000 | +29.7% | 601,738 | -1.5% | 0.01% | +27.3% |
| Q3 2021 | $34,703,000 | +22.3% | 610,866 | -5.3% | 0.01% | +22.2% |
| Q2 2021 | $28,377,000 | -2.1% | 644,788 | +9.8% | 0.01% | -10.0% |
| Q1 2021 | $28,974,000 | +2.5% | 587,496 | -12.5% | 0.01% | 0.0% |
| Q4 2020 | $28,258,000 | -11.8% | 671,221 | -4.1% | 0.01% | -28.6% |
| Q3 2020 | $32,045,000 | -11.0% | 700,013 | -2.3% | 0.01% | -12.5% |
| Q2 2020 | $35,991,000 | -2.2% | 716,838 | +0.2% | 0.02% | -15.8% |
| Q1 2020 | $36,797,000 | -15.0% | 715,503 | +2.1% | 0.02% | +18.8% |
| Q4 2019 | $43,295,000 | +7.8% | 700,791 | +4.8% | 0.02% | 0.0% |
| Q3 2019 | $40,175,000 | -23.9% | 668,691 | +6.8% | 0.02% | -23.8% |
| Q2 2019 | $52,827,000 | -12.1% | 626,058 | -0.5% | 0.02% | -12.5% |
| Q1 2019 | $60,083,000 | +36.0% | 629,013 | +0.9% | 0.02% | +20.0% |
| Q4 2018 | $44,172,000 | -14.4% | 623,630 | +3.2% | 0.02% | 0.0% |
| Q3 2018 | $51,620,000 | -25.0% | 604,006 | +1.7% | 0.02% | -25.9% |
| Q2 2018 | $68,825,000 | +43.4% | 593,847 | +0.1% | 0.03% | +35.0% |
| Q1 2018 | $48,005,000 | +45.9% | 593,310 | +5.8% | 0.02% | +42.9% |
| Q4 2017 | $32,901,000 | +25.0% | 560,670 | -0.3% | 0.01% | +16.7% |
| Q3 2017 | $26,320,000 | +31.9% | 562,394 | +1.4% | 0.01% | +33.3% |
| Q2 2017 | $19,961,000 | +56.9% | 554,777 | +34.3% | 0.01% | +50.0% |
| Q1 2017 | $12,723,000 | +111.2% | 413,089 | +129.7% | 0.01% | +100.0% |
| Q4 2016 | $6,024,000 | +729.8% | 179,824 | +558.4% | 0.00% | – |
| Q3 2016 | $726,000 | +28.5% | 27,313 | +6.6% | 0.00% | – |
| Q2 2016 | $565,000 | -24.9% | 25,613 | 0.0% | 0.00% | – |
| Q1 2016 | $752,000 | -10.8% | 25,613 | +0.4% | 0.00% | -100.0% |
| Q4 2015 | $843,000 | -7.4% | 25,513 | +1.2% | 0.00% | 0.0% |
| Q3 2015 | $910,000 | -16.4% | 25,213 | +4.1% | 0.00% | 0.0% |
| Q2 2015 | $1,088,000 | +217.2% | 24,213 | +116.2% | 0.00% | – |
| Q1 2015 | $343,000 | – | 11,201 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Krensavage Asset Management, LLC | 476,042 | $45,472,000 | 12.29% |
| Stonepine Capital Management, LLC | 60,840 | $5,811,000 | 3.34% |
| ACUTA CAPITAL PARTNERS, LLC | 61,000 | $5,827,000 | 2.77% |
| Virtus ETF Advisers LLC | 10,634 | $1,016,000 | 2.16% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 61,000 | $5,827,000 | 2.15% |
| ARMISTICE CAPITAL, LLC | 372,000 | $35,533,000 | 1.94% |
| Matarin Capital Management, LLC | 209,403 | $20,002,000 | 1.46% |
| Monashee Investment Management LLC | 50,000 | $4,776,000 | 1.10% |
| Granahan Investment Management | 151,322 | $14,454,000 | 0.78% |
| ALGERT GLOBAL LLC | 13,186 | $1,260,000 | 0.72% |